Want to see GB:HEMO full AI Analyst Report?

HemoGenyx Pharmaceuticals Plc (HEMO) Price & Analysis

37 Followers

HEMO Stock Chart & Stats

568.00 p

-12.50 p(-3.23%)

At close: Jan 09 4:00 PM EST

568.00 p

-12.50 p(-3.23%)

Day’s Range― - ―

52-Week Range124.00 p - 1,800.00 p

Previous CloseN/A

Volume114.00

Average Volume (3M)113.41K

Market Cap

£51.00M

Enterprise Value53.32M

Total Cash (Recent Filing)£1.59M

Total Debt (Recent Filing)£2.00M

Price to Earnings (P/E)―

Beta0.29

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.21

Shares Outstanding6,799,961

10 Day Avg. Volume30,447

30 Day Avg. Volume113,406

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)21.26

Price to Sales (P/S)0.00

P/FCF Ratio-7.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Niche Hematology/oncology FocusA concentrated R&D focus on hematology and oncology provides durable competitive positioning in specialized clinical areas. This niche expertise supports targeted partnerships, regulatory pathways, and long-term value capture if clinical progress validates programs, making the business model resilient to broad market cycles.

Debt Reduction 2023–2025Lowering nominal debt across 2023–2025 meaningfully reduces near-term financing strain for a loss-making biotech. This structural reduction improves liquidity flexibility, lowers interest burden risk, and modestly extends runway versus constant-debt scenarios, aiding execution of clinical milestones without as frequent refinancing.

Improving Operating Cash BurnA decline in absolute operating cash burn in 2025 versus 2024 indicates management has begun to moderate cash consumption. If sustained, this structural improvement lengthens runway, reduces reliance on dilutive financing, and increases the probability the firm can reach value-inflection clinical or licensing events before requiring large capital raises.

Bears Say

Pre-revenue ProfileAbsence of product revenue means the company is fully dependent on external capital and milestone/licensing outcomes to fund operations. This lack of recurring cash inflows creates persistent funding risk and makes long-term viability contingent on successful clinical progress or partner deals rather than internal cash generation.

Widening Net LossesA material increase in annual net losses accelerates equity depletion and heightens near-term financing needs. For a pre-revenue biotech, growing losses reduce the time available to reach inflection points, increase dilution risk when raising capital, and pressure resources for sustained R&D programs absent external funding.

Leverage & Shrinking Equity CushionDebt levels exceeding a materially reduced equity base increase solvency and refinancing risk for a loss-making enterprise. A thin equity cushion limits ability to absorb further losses, raises creditor priority over shareholders, and makes future financing likelier to be dilutive or expensive, constraining long-term strategic optionality.

HemoGenyx Pharmaceuticals Plc News

Hemogenyx Wins Full Shareholder Backing at AGM, Secures New Capital Flexibility

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an announcement. Hemogenyx Pharmaceuticals reported that shareholders approved all resolutions...

3d ago

Hemogenyx Sends 2025 Annual Report and Sets June AGM

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals has dispatched its Annual Report and...

29d ago

Hemogenyx reshapes incentives with new options and extended investor warrants

An update from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) is now available. Hemogenyx Pharmaceuticals has granted a total...

1M ago

Hemogenyx advances lead CAR-T trial and secures funding to complete Phase 1

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) just unveiled an update. Hemogenyx Pharmaceuticals reported its final audited results for...

2M ago

Hemogenyx Raises £3m to Accelerate HG-CT-1 Trials and Early Commercialisation

The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ). Hemogenyx Pharmaceuticals has raised £3 million...

2M ago

Hemogenyx Files Annual FDA IND Report as AML CAR‑T Trial Shows Early Promise

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an update. Hemogenyx Pharmaceuticals has filed its annual Investigational New...

3M ago

Hemogenyx Advances HG-CT-1 CAR-T Program With Manufacturing Transfer and Trial Expansion

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has issued an announcement. Hemogenyx Pharmaceuticals has completed the technology transfer of...

3M ago

Hemogenyx Pharmaceuticals Updates Share Capital and Voting Rights Structure

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals plc, a clinical-stage biopharmaceutical group listed...

4M ago

Hemogenyx Raises £118,632 Through Warrant Exercise and Expands Share Capital

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has shared an update. Hemogenyx Pharmaceuticals has received notices to exercise warrants...

4M ago

Hemogenyx Raises £2.5m to Advance CAR-T Trials in Adult and Pediatric AML

HemoGenyx Pharmaceuticals Plc ( ($GB:HEMO) ) has provided an announcement. Hemogenyx Pharmaceuticals has raised £2.5 million from a...

5M ago

HEMO FAQ

What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?

HemoGenyx Pharmaceuticals Plc lowest share price was 124.00 p and its highest was 1800.00 p in the past 12 months.

What is HemoGenyx Pharmaceuticals Plc’s market cap?

HemoGenyx Pharmaceuticals Plc’s market cap is £51.00M.

When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?

HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 82 days.

How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?

HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.

Is HemoGenyx Pharmaceuticals Plc overvalued?

According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HemoGenyx Pharmaceuticals Plc pay dividends?

HemoGenyx Pharmaceuticals Plc does not currently pay dividends.

What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?

HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?

HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.

What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?

HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.

Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?

Currently, no hedge funds are holding shares in GB:HEMO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HemoGenyx Pharmaceuticals Plc Stock Smart Score

Underperform

News Sentiment

Neutral

Bullish news 50%
Bearish news 50%

Technicals

Fundamentals

Return on Equity

-2807.75%

Trailing 12-Months

Asset Growth

-0.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.